3-acetyl-2-(2-hydroxy-5-methoxyphenyl)benzothiazoline | 105129-60-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 3-acetyl-2-(2-hydroxy-5-methoxyphenyl)benzothiazoline
• 英文别名: 1-[2-(2-Hydroxy-5-methoxyphenyl)-1,3-benzothiazol-3(2H)-yl]ethan-1-one；1-[2-(2-hydroxy-5-methoxyphenyl)-2H-1,3-benzothiazol-3-yl]ethanone
• CAS: 105129-60-0
• 化学式: C₁₆H₁₅NO₃S
• 分子量: 301.366
• InChiKey: ROSJMNJJOXFJGH-UHFFFAOYSA-N

物化性质

• 熔点：
  205.5-206.5 °C
• 沸点：
  502.7±50.0 °C(Predicted)
• 密度：
  1.327±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  75.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-acetyl-2-(2-hydroxy-5-methoxyphenyl)benzothiazoline 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 4.0h， 生成 1-[2-[5-methoxy-2-[4-(methylamino)butoxy]phenyl]-2H-1,3-benzothiazol-3-yl]ethanone
  参考文献：
  名称：

  新型钙拮抗剂。苯并噻唑啉衍生物的合成及其构效关系研究。

  摘要：

  研究了一系列具有苯并噻唑啉骨架的新型化合物的相对于Ca2 +拮抗活性的结构活性关系（SAR）。作为测试化合物，合成了3-酰基-2-芳基苯并噻唑啉的类似物（3）。苯并噻唑啉衍生物（3）比相应的噻唑烷衍生物（2）具有更高的Ca2 +拮抗活性。研究了取代基R1-R4，氨基烷氧基和R2的取代位置以及亚甲基链的长度对生物活性的影响。化合物4 [3-乙酰基-2- [5-甲氧基-2- [4- [N-甲基-N-（3,4,5-三甲氧基苯乙基）氨基]丁氧基]苯基]苯并噻唑啉盐酸盐]显示出有效的Ca2 +拮抗活性体外对Langendorff灌注兔心脏中Na +向内快速通道和Ca2 +向内缓慢通道的双重抑制。

  DOI：

  10.1021/jm00400a006
• 作为产物：
  描述：

  [2-(3-acetyl-2H-1,3-benzothiazol-2-yl)-4-methoxyphenyl] (2R,4R)-3-acetyl-2-naphthalen-1-yl-1,3-thiazolidine-4-carboxylate 生成 3-acetyl-2-(2-hydroxy-5-methoxyphenyl)benzothiazoline
  参考文献：
  名称：

  IVAO, DZYUNITI;ISO, TADASI;KAVASIMA, JOITI

  摘要：

  DOI：

文献信息

• Synthesis and calcium antagonistic activity of (+)-(R)- and (-)-(S)-3-acetyl-2-(5-methoxy-2-(4-(N-methyl-N-(3,4,5-trimethoxyphenethyl)amino)butoxy)phenyl)benzothiazoline hydrochloride.
  作者：Masanobu FUJITA、Atsutoshi OTA、Susumu ITO、Koji YAMAMOTO、Yoichi KAWASHIMA、Tadashi ISO、Jun-ichi IWAO

  DOI：10.1248/cpb.38.936

  日期：——

  SA2572 ((±)-1), 3-acetyl-2-[5-methoxy-2-[-[N-methyl-N-(3, 4, 5-trimethoxyphenethyl)amino]butoxy]phenyl]-benzothiazoline hydrocholoride is a newly synthesized Ca2+ antagonist having a inhibitory effect on the fast Na+ inward channel In order to clarify the absolute configurations and the pharmacological properties of both enantiomers, compounds ((+)-1 and (-)-1) were synthesized. The configurations of these compounds were assigned on the basis of an X-ray crystallographic analysis of synthetic precursor (5). The in vitro Ca2+ channel blocking activities of (+)-1 and (-)-1 were evaluated in terms of the inhibitory activities on depolarization-induced contraction of guinea pig taenia cecum and rabbit aorta. The in vivo efficacy of the enantiomers was evaluated with their hypotensive effects in spontaneously hypertensive rats. Compound (-)-1 showed more potent Ca2+ antagonistic activities on guinea pig taenia cecum and rabbit aorta and the hypotensive effect than those activities of (+)-1. In the electrophysiological study of Langendorff perfused rabbit hearts, compound (+)-1 showed more potent inhibitory effect on the fast Na+ inward channel than that of compound (-)-1, and an approximately equal potent inhibitory effect on the slow Ca2+ inward channel as compared (-)-1. Stereoselectivity of the pharmacological activity was found.

  SA2572 ((±)-1)，即3-乙酰基-2-[5-甲氧基-2-[N-甲基-N-(3，4，5-三甲氧基苯乙基)氨基]丁氧基]苯基]-苯并噻唑啉盐酸盐，是一种新合成的Ca2+拮抗剂，具有抑制快速Na+内向通道的作用。为了阐明两种对映体((+)-1和(-)-1)的绝对构型和药理学特性，进行了合成。通过合成前体(5)的X射线晶体学分析，确定了这些化合物的构型。在体外，评估了(+)-1和(-)-1对豚鼠结肠带和兔主动脉去极化诱导收缩的抑制活性，从而评价了它们对Ca2+通道的阻断活性。在体内，通过评估对映体对自发性高血压大鼠的降压效果来评价其疗效。化合物(-)-1在豚鼠结肠带和兔主动脉上表现出比(+)-1更强的Ca2+拮抗活性及降压效果。在Langendorff灌流兔心电生理学研究中，化合物(+)-1对快速Na+内向通道的抑制作用比化合物(-)-1更强，而对慢速Ca2+内向通道的抑制作用与(-)-1相当。发现了药理活性的立体选择性。
• Kappa-opioid receptor agonist comprising 2-phenylbenzothiazoline derivative
  申请人：Tokai Maki

  公开号：US20050113430A1

  公开（公告）日：2005-05-26

  The present invention provides κ opioid receptor agonists comprising 2-phenylbenzothiazoline derivatives. The present invention relates to κ opioid receptor agonists comprising compounds or salts thereof having the chemical structure represented by the general formula [I]. Namely, it is important for exhibition of the κ opioid receptor agonist actions to have an alkyl group having an amino group at a phenyl group of 2-phenylbenzothiazoline as a substituent and to have an acyl group at a nitrogen atom of 2-phenylbenzothiazoline, wherein R is alkyl having the amino group as the substituent; and R 1 is acyl.

  本发明提供了包含2-苯基苯并噻唑衍生物的κ阿片受体激动剂。本发明涉及化学结构式[I]所表示的化合物或其盐，其包含κ阿片受体激动剂，即在2-苯基苯并噻唑的苯基上具有氨基取代基的烷基取代基，并在2-苯基苯并噻唑的氮原子上具有酰基取代基，这对于展示κ阿片受体激动剂作用非常重要，其中R是具有氨基取代基的烷基取代基；R1是酰基。
• Method for treating pain or pruritis by administering opinoid receptor agonist comprising 2-phenylbenzothiazoling derivative
  申请人：Tokai Maki

  公开号：US20060205796A1

  公开（公告）日：2006-09-14

  A method of treating pain or pruritis comprising administering to a patient in need thereof a pharmaceutically effective amount of a κ opioid receptor agonist of the formula wherein R is an alkyl having an amino group as a substituent; and R 1 is acyl.

  一种治疗疼痛或瘙痒的方法，包括向需要治疗的患者给予药效有效量的κ阿片受体激动剂，该激动剂的化学式为其中R是具有氨基基团的烷基；R1是酰基。
• KAPPA-OPIOID RECEPTOR AGONIST COMPRISING 2-PHENYLBENZOTHIAZOLINE DERIVATIVE
  申请人：SANTEN PHARMACEUTICAL CO., LTD.

  公开号：EP1496053A1

  公开（公告）日：2005-01-12

  The present invention provides κ opioid receptor agonists comprising 2-phenylbenzothiazoline derivatives. The present invention relates to κ opioid receptor agonists comprising compounds or salts thereof having the chemical structure represented by the general formula [I]. Namely, it is important for exhibition of the κ opioid receptor agonist actions to have an alkyl group having an amino group at a phenyl group of 2-phenylbenzothiazoline as a substituent and to have an acyl group at a nitrogen atom of 2-phenylbenzothiazoline, wherein R is alkyl having the amino group as the substituent; and R1 is acyl.

  本发明提供了由 2-苯基苯并噻唑啉衍生物组成的 κ 阿片受体激动剂。本发明涉及由具有通式[I]所代表的化学结构的化合物或其盐组成的κ阿片受体激动剂。也就是说，对于展示κ阿片受体激动剂的作用而言，重要的是在 2-苯基苯并噻唑啉的苯基上具有氨基的烷基作为取代基，并且在 2-苯基苯并噻唑啉的氮原子上具有酰基、 其中 R 是以氨基为取代基的烷基；R1 是酰基。
• Kappa-opioid receptor agonist comprising a 2-phenylbenzothiazoline derivative
  申请人：SANTEN PHARMACEUTICAL CO., LTD.

  公开号：EP1496053B1

  公开（公告）日：2012-06-20